Cargando…

H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice

Hemolysis, oxidative stress, inflammation, vaso-occlusion, and organ infarction are hallmarks of sickle cell disease (SCD). We have previously shown that increases in heme oxygenase-1 (HO-1) activity detoxify heme and inhibit vaso-occlusion in transgenic mouse models of SCD. HO-1 releases Fe(2+) fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Vercellotti, Gregory M., Khan, Fatima B., Nguyen, Julia, Chen, Chunsheng, Bruzzone, Carol M., Bechtel, Heather, Brown, Graham, Nath, Karl A., Steer, Clifford J., Hebbel, Robert P., Belcher, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029007/
https://www.ncbi.nlm.nih.gov/pubmed/24860503
http://dx.doi.org/10.3389/fphar.2014.00079
_version_ 1782317146192216064
author Vercellotti, Gregory M.
Khan, Fatima B.
Nguyen, Julia
Chen, Chunsheng
Bruzzone, Carol M.
Bechtel, Heather
Brown, Graham
Nath, Karl A.
Steer, Clifford J.
Hebbel, Robert P.
Belcher, John D.
author_facet Vercellotti, Gregory M.
Khan, Fatima B.
Nguyen, Julia
Chen, Chunsheng
Bruzzone, Carol M.
Bechtel, Heather
Brown, Graham
Nath, Karl A.
Steer, Clifford J.
Hebbel, Robert P.
Belcher, John D.
author_sort Vercellotti, Gregory M.
collection PubMed
description Hemolysis, oxidative stress, inflammation, vaso-occlusion, and organ infarction are hallmarks of sickle cell disease (SCD). We have previously shown that increases in heme oxygenase-1 (HO-1) activity detoxify heme and inhibit vaso-occlusion in transgenic mouse models of SCD. HO-1 releases Fe(2+) from heme, and the ferritin heavy chain (FHC) ferroxidase oxidizes Fe(2+) to catalytically inactive Fe(3+) inside ferritin. FHC overexpression has been shown to be cytoprotective. In this study, we hypothesized that overexpression of FHC and its ferroxidase activity will inhibit inflammation and microvascular stasis in transgenic SCD mice in response to plasma hemoglobin. We utilized a Sleeping Beauty (SB) transposase plasmid to deliver a human wild-type-ferritin heavy chain (wt-hFHC) transposable element by hydrodynamic tail vein injections into NY1DD SCD mice. Control SCD mice were infused with the same volume of lactated Ringer’s solution (LRS) or a human triple missense FHC (ms-hFHC) plasmid with no ferroxidase activity. 8 weeks later, LRS-injected mice had ~40% microvascular stasis (% non-flowing venules) 1 h after infusion of stroma-free hemoglobin, while mice overexpressing wt-hFHC had only 5% stasis (p < 0.05), and ms-hFHC mice had 33% stasis suggesting vascular protection by ferroxidase active wt-hFHC. The wt-hFHC SCD mice had marked increases in splenic hFHC mRNA and hepatic hFHC protein, ferritin light chain (FLC), 5-aminolevulinic acid synthase (ALAS), heme content, ferroportin, nuclear factor erythroid 2-related factor 2 (Nrf2), and HO-1 activity and protein. There was also a decrease in hepatic activated nuclear factor-kappa B (NF-κB) phospho-p65 and vascular cell adhesion molecule-1 (VCAM-1). Inhibition of HO-1 activity with tin protoporphyrin demonstrated HO-1 was not essential for the protection by wt-hFHC. We conclude that wt-hFHC ferroxidase activity enhances cytoprotective Nrf2-regulated proteins including HO-1, thereby resulting in decreased NF-κB-activation, adhesion molecules, and microvascular stasis in transgenic SCD mice.
format Online
Article
Text
id pubmed-4029007
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40290072014-05-23 H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice Vercellotti, Gregory M. Khan, Fatima B. Nguyen, Julia Chen, Chunsheng Bruzzone, Carol M. Bechtel, Heather Brown, Graham Nath, Karl A. Steer, Clifford J. Hebbel, Robert P. Belcher, John D. Front Pharmacol Pharmacology Hemolysis, oxidative stress, inflammation, vaso-occlusion, and organ infarction are hallmarks of sickle cell disease (SCD). We have previously shown that increases in heme oxygenase-1 (HO-1) activity detoxify heme and inhibit vaso-occlusion in transgenic mouse models of SCD. HO-1 releases Fe(2+) from heme, and the ferritin heavy chain (FHC) ferroxidase oxidizes Fe(2+) to catalytically inactive Fe(3+) inside ferritin. FHC overexpression has been shown to be cytoprotective. In this study, we hypothesized that overexpression of FHC and its ferroxidase activity will inhibit inflammation and microvascular stasis in transgenic SCD mice in response to plasma hemoglobin. We utilized a Sleeping Beauty (SB) transposase plasmid to deliver a human wild-type-ferritin heavy chain (wt-hFHC) transposable element by hydrodynamic tail vein injections into NY1DD SCD mice. Control SCD mice were infused with the same volume of lactated Ringer’s solution (LRS) or a human triple missense FHC (ms-hFHC) plasmid with no ferroxidase activity. 8 weeks later, LRS-injected mice had ~40% microvascular stasis (% non-flowing venules) 1 h after infusion of stroma-free hemoglobin, while mice overexpressing wt-hFHC had only 5% stasis (p < 0.05), and ms-hFHC mice had 33% stasis suggesting vascular protection by ferroxidase active wt-hFHC. The wt-hFHC SCD mice had marked increases in splenic hFHC mRNA and hepatic hFHC protein, ferritin light chain (FLC), 5-aminolevulinic acid synthase (ALAS), heme content, ferroportin, nuclear factor erythroid 2-related factor 2 (Nrf2), and HO-1 activity and protein. There was also a decrease in hepatic activated nuclear factor-kappa B (NF-κB) phospho-p65 and vascular cell adhesion molecule-1 (VCAM-1). Inhibition of HO-1 activity with tin protoporphyrin demonstrated HO-1 was not essential for the protection by wt-hFHC. We conclude that wt-hFHC ferroxidase activity enhances cytoprotective Nrf2-regulated proteins including HO-1, thereby resulting in decreased NF-κB-activation, adhesion molecules, and microvascular stasis in transgenic SCD mice. Frontiers Media S.A. 2014-04-17 /pmc/articles/PMC4029007/ /pubmed/24860503 http://dx.doi.org/10.3389/fphar.2014.00079 Text en Copyright © 2014 Vercellotti, Khan, Nguyen, Chen, Bruzzone, Bechtel, Brown, Nath, Steer, Hebbel and Belcher. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Vercellotti, Gregory M.
Khan, Fatima B.
Nguyen, Julia
Chen, Chunsheng
Bruzzone, Carol M.
Bechtel, Heather
Brown, Graham
Nath, Karl A.
Steer, Clifford J.
Hebbel, Robert P.
Belcher, John D.
H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
title H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
title_full H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
title_fullStr H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
title_full_unstemmed H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
title_short H-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
title_sort h-ferritin ferroxidase induces cytoprotective pathways and inhibits microvascular stasis in transgenic sickle mice
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4029007/
https://www.ncbi.nlm.nih.gov/pubmed/24860503
http://dx.doi.org/10.3389/fphar.2014.00079
work_keys_str_mv AT vercellottigregorym hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT khanfatimab hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT nguyenjulia hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT chenchunsheng hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT bruzzonecarolm hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT bechtelheather hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT browngraham hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT nathkarla hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT steercliffordj hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT hebbelrobertp hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice
AT belcherjohnd hferritinferroxidaseinducescytoprotectivepathwaysandinhibitsmicrovascularstasisintransgenicsicklemice